Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin

Drug Metabolism and Disposition

Volumn 36, Issue 5, 2008, Pages 904-910

  Bains, Onkar S ^a   Takahashi, Ryan H ^a   Pfeifer, Tom A ^a   Grigliatti, Thomas A ^a   Reid, Ronald E ^a   Riggs, K Wayne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROBENZALDEHYDE; ALDEHYDE DERIVATIVE; ALDOKETOREDUCTASE 1A1; DAUNORUBICIN; DAUNORUBICINOL; DOXORUBICIN; DOXORUBICINOL; GLYCERALDEHYDE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ALLELE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALDEHYDE REDUCTASE; ALLELES; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; DAUNORUBICIN; DOXORUBICIN; HUMANS; RECOMBINANT PROTEINS; VARIATION (GENETICS);

EID: 42449101792     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018895     Document Type: Article

References (40)

1. Adamcova M, Pelouch V, Gersl V, Kaplanova J, Mazurova Y, Simunek T, Klimtova I, and Hrdina R (2003) Protein profiling in daunorubicin-induced cardiomyopathy. Gen Physiol Biophys 22:411-419.
2. 2+-ATPase gene transcription. Circ Res 86:8-14.
3. Boucek RJ Jr, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, and Fleischer S (1987) The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: a correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262:15851-15856.
4. Chung SS and Chung SK (2003) Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem 10:1375-1387.
5. Cummings J, Anderson L, Willmott N, and Smyth JF (1991) The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 27:532-535.
6. Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M (2002) Pharmacokinetic pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41:431-444.
7. Di Luccio E, Elling RA, and Wilson DK (2006) Identification of a novel NADH-specific aldo-keto reductase using sequence and structural homologies. Biochem J 400:105-114.
8. Donaghue KC, Margan SH, Chan AK, Holloway B, Silink M, Rangel T, and Bennetts B (2005) The association of aldose reductase gene (AKR1B1) polymorphisms diabetic neuropathy in adolescents. Diabet Med 22:1315-1320.
9. Doroshow JH (1983) Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460-472.
10. Fassas A and Anagnostopoulos A (2005) The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 46:795-802.
11. Hunault-Berger M, Milpied N, Bernard M, Jouet JP, Delain M, Desablens B, Sadoun A, Guilhot F, Casassus P, and Ifrah N (2001) Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Leukemia 15:898-902.
12. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, and Torti FM (1990) Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A 87:4275-4279.
13. Jez JM, Bennett MJ, Schlegel BP, Lewis M, and Penning TM (1997) Comparative anatomy of the aldo-keto reductase superfamily. Biochem J 326:625-636.
14. Jin Y and Penning TM (2007) Aldo-keto reductases and bioactivation/ detoxification. Ann Rev Pharmacol Toxicol 47:10.1-10.30.
15. Kim DS, Kim HR, Woo EF, Hong ST, Chae HJ, and Chae SW (2005) Inhibitory effects of rosmarinic acid on Adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. Biochem Pharmacol 70:1066-1078.
16. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, et al. (2004) Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25(11):2177-2181.
17. Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P, and Chancock S (2007) Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 121:161-168.
18. Licata S, Saponiero A, Mordente A, and Minotti G (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13:414-420.
19. Lipp HP and Bokemeyer C (1999) Anthracyclines and other intercalating agents, in Anticancer Drug Toxicity: Prevention, Management and Clinical Pharmacokinetics (Lipp HP ed) pp 81-113, Marcel Dekker, New York.
20. Lord SJ, Mack WJ, Van Den Berg D, Pike MC, Ingles SA, Haiman CA, Wang W, Parisky YR, Hodis HN, and Ursin G (2005) Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study. Breast Cancer Res 7:R336-R344.
21. Menna P, Recalcati S, Cairo G, and Minotti G (2007) An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:80-85.
22. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, and Possati G (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines: novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 95:1595-1605.
23. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
24. Mordente A, Meucci E, Martorana GE, Giardina B, and Minott G (2001) Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52:83-88.
25. O'Connor T, Ireland LS, Harrison DJ, and Hayes JD (1999) Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J 343:487-504.
26. Palackal NT, Burczynski ME, Harvey RG, and Penning TM (2001) The ubiquitous aldehyde reductase (AKR1A1) oxidizes proximate carcinogen trans-dihydrodiols to o-quinones: Potential role in polycyclic aromatic hydrocarbon activation. Biochemistry 40:10901-10910.
27. Penning TM (2005) Introduction and overview of the aldo-keto reductase superfamily, in Aldo-Keto Reductases and Toxicant Metabolism (Penning TM and Petrash JM eds) pp 3-20, American Chemical Society, Washington DC.
28. Penning TM and Drury JE (2007) Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 464:241-250.
29. Plebuch M, Soldan M, Hungerer C, Koch L, and Maser E (2007) Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett 255:49-56.
30. Rabbani A, Finn RM, and Ausio J (2005) The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioassays 27:50-56.
31. Rajagopalan S, Politi PM, Sinha BK, and Myers CE (1988) Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 48:4766-4769.
32. Schlegel BP, Jez JM, and Penning TM (1998) Mutagenesis of 3α-hydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldo-keto reductases. Biochemistry 37:3538-3548.
33. Shan K, Lincoff AM, and Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58.
34. Simunek T, Klimtova L, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, Hrdina R, Gersl V, and Ponka P (2005) Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol Res 51:223-231.
35. Singal PK, Li T, Kumar D, Danelisen I, and Iliskovic N (2000) Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 207:77-85.
36. Sivenius K, Niskanen L, Voutilainen-Kaunisto R, Laakso M, and Uusitupa M (2004) Aldose reductase gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Diabet Med 21:1325-1333.
37. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T and Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389-405.
38. Wojtacki J, Lewicka-Nowak E, and Lesniewski-Kmak K (2000) Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention review of the literature. Med Sci Monit 6:411-420.
39. Wold LE, Aberle NS, and Ren J (2005) Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect Prev 29:294-299.
40. Yen HC, Oberley TD, Vichitbandha S, Ho YS, and St Clair DK (1996) The protective role of manganese superoxide dismutase against Adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98:1253-1260.